Zobrazeno 31 - 40
of 112
pro vyhledávání: '"Wungki Park"'
Autor:
Wungki Park, Eileen Mary O'Reilly, Junji Furuse, Chung-Pin Li, Do-Youn Oh, Rocio Garcia-Carbonero, Gaël Roth, Ho-Jin Lee, Pranob P. Bhattacharya, Diarmuid Martin Moran, Jianning Yang, Futoshi Kunieda
Publikováno v:
Journal of Clinical Oncology. 41:TPS782-TPS782
TPS782 Background: GN is a first-line treatment option for patients (pts) with mPC. Poor prognosis and low 5-year survival rate ( < 5%) with mPC highlight the need for new therapeutics. Claudin 18.2 (CLDN18.2), a tight junction protein expressed excl
Autor:
Anthony W. Tolcher, Wungki Park, Judy S. Wang, Alexander I. Spira, Pasi A. Janne, Ho-Jin Lee, Stanley Gill, Patricia LoRusso, Benjamin Herzberg, Jonathan W. Goldman, Daniel Morgensztern, Jordan Berlin, Anup Kasi, Hisaki Fujii, Meredith Pelster
Publikováno v:
Journal of Clinical Oncology. 41:TPS764-TPS764
TPS764 Background: Kirsten rat sarcoma (KRAS) G12D is a point mutation observed in various cancer types including pancreatic ductal cancer, colon adenocarcinoma, and lung cancers. ASP3082 is a novel small-molecule proteolysis-targeting chimeric degra
Autor:
Fergus Keane, Joshua David Schoenfeld, Fionnuala Crowley, Catherine Anne O'Connor, Charlie White, Carly Schwartz, Robin Brenner, Mary Larsen, Wungki Park, Anna M. Varghese, Kenneth H. Yu, Jia Li, Alice Zervoudakis, Zoe Goldberg, Joanne F. Chou, Santosha Vardhana, Marsha Reyngold, Christopher H Crane, Richard Tuli, Eileen Mary O'Reilly
Publikováno v:
Journal of Clinical Oncology. 41:725-725
725 Background: Immune checkpoint blockade (ICB) has a modest signal in the treatment of patients with genomically unselected pancreatic cancer (PDAC). Synergistic effects of combined radiotherapy and ICB are postulated. Preliminary results of a phas
Autor:
Darren Cowzer, Risha Huq, Maria Perry, Fergus Keane, Wungki Park, Imane H. El Dika, Danny Khalil, Jinru Shia, Carlie S. Sigel, Chaitanya Bandlamudi, Michael F. Berger, David B. Solit, Eileen Mary O'Reilly, Ghassan K. Abou-Alfa, James J. Harding
Publikováno v:
Journal of Clinical Oncology. 41:513-513
513 Background: Isocitrate dehydrogenase 1 and 2 (IDH1/2) play a key role in cellular metabolism and epigenetic regulation. Conserved missense IDH1 mutations lead to an accumulation of the onco-metabolite 2-hydroxygluterate, which drives oncogenesis
Autor:
Eileen M. O'Reilly, Kenneth H. Yu, Caitlin A. McIntyre, David P. Kelsen, Wungki Park, Jorge S. Reis-Filho, Nima Ghalehsari, Ghassan K. Abou-Alfa, Liying Zhang, Danny N. Khalil, Nadeem Riaz, Xin Pei, Sree Bhavani Chalasani, Joanne F. Chou, Jiapeng Chen, Nicolas Lecomte, Vinod P. Balachandran, Nikolaus Schultz, Imane El Dika, M. Capanu, Pier Selenica, James J. Harding, Anna M. Varghese, Timothy A. Chan, Winston Wong, Vladimir Makarov, Michael F. Berger, S.N. Powell, Mark E. Robson, Christine A. Iacobuzio-Donahue, Zoe McKinnell
Publikováno v:
Clin Cancer Res
Purpose: Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response–targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in max
Autor:
Maida Hafiz, Paul R. Walker, Rita Chiari, Abdul Rafeh Naqash, Cynthia R. Cherry, Gregory A. Otterson, Jarred Burkart, Vaia Florou, Sandip H. Patel, Dwight H. Owen, Gilberto Lopes, Yukihiro Toi, Shunichi Sugawara, Wungki Park, Mavish Muzaffar, Andrea De Giglio, Jun Sugisaka, Biagio Ricciuti
Publikováno v:
Cancer Immunology, Immunotherapy. 69:1177-1187
The original version of this article unfortunately contained a mistake. The second sentence of the section "irAEs and ICI efficacy" should read as.
Autor:
Ashkon Rahbari, Wungki Park, Victoria M. Villaflor, Lauren Chiec, Bhoomika Sukhadia, Nisha Mohindra, Victor Wang, Garrett M. Frampton, Sangmin Chang, Jeffrey S. Ross, Si Wang, Zachary R. Chalmers, Siraj M. Ali, Jonathan F. Anker, Vaia Florou, Sang Ha Shin, Jeffrey H. Chuang, Pedro Viveiros, Lee Chun Park, Diana Saravia, Gilberto Lopes, Muhammad Mubbashir Sheikh, Young Kwang Chae, Ethan Sokol, Michael Oh
Publikováno v:
Journal of Thoracic Oncology. 14:1807-1817
Introduction Presently, programmed death ligand 1 is the most commonly used biomarker to predict response to immune checkpoint inhibitors (ICIs) in NSCLC. Owing to its several limitations, there is continuous search for more precise and reliable mark
Autor:
Alejandro Jiménez-Sánchez, Yubin Xie, Roshan Sharma, Tin Yi Chu, Vincent Liu, Wungki Park, Akimasa Hayashi, Shigeaki Umeda, Linas Mazutis, Tal Nawy, Christine Iacobuzio-Donahue, Dana Pe’er
Publikováno v:
Cancer Research. 82:279-279
Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths with very few treatment options and low-success rates. Generally speaking metastatic PDAC remains incurable. One reason behind PDAC morbidity and
Autor:
Wungki Park, Fergus Keane, Chaitanya Bandlamudi, Mark Donoghue, Paulino Tallón de Lara, James J. Harding, Danny Khalil, Zoe McKinnell, Michelle Sterpi, Will Cao, Imane H. El Dika, Vinod P. Balachandran, Kevin Soares, Anna M. Varghese, Kenneth H. Yu, David Paul Kelsen, Christine A Iacobuzio-Donahue, Ghassan K. Abou-Alfa, David B. Solit, Eileen Mary O'Reilly
Publikováno v:
Journal of Clinical Oncology. 40:4083-4083
4083 Background: Several immunomodulatory molecules (PD-L1, B7H4, and CD276) have been associated with biliary tract cancer (BTC) subgroups, suggesting potential value to immune checkpoint blockade (ICB) in this lethal disease. Phase II monotherapy (
Autor:
Wungki Park, Eileen Mary O'Reilly, Junji Furuse, Chung-Pin Li, Do-Youn Oh, Rocio Garcia-Carbonero, Gaël Roth, Ho-Jin Lee, Futoshi Kunieda
Publikováno v:
Journal of Clinical Oncology. 40:TPS4186-TPS4186
TPS4186 Background: GN is a first-line treatment option for patients (pts) with mPC. Poor prognosis and low 5-year survival rate ( < 5%) of pts with mPC highlight the need for new therapeutics. Claudin 18.2 (CLDN18.2), a tight junction protein expres